+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06701903

Randomized Study of ITI-1284 Tablets Versus Placebo for Treating Generalized Anxiety Disorder in Patients with Inadequate Prior Treatment Response

Led by Intra-Cellular Therapies, Inc. · Updated on 2026-11-03

570

Participants Needed

51

Research Sites

40 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug ITI-1284 as a monotherapy treatment in patients diagnosed with moderate to severe Generalized Anxiety Disorder GAD who have not responded adequately to previous GAD treatments. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to assess the efficacy, safety, and tolerability of ITI-1284 in this patient population. Participants are randomly assigned to one of three groups ITI-1284 10 mg tablet, ITI-1284 20 mg tablet, or a matching placebo, all taken once daily by sublingual administration. The study compares these doses to placebo over a treatment period, with assessments planned at Week 6. During the study, participants will be monitored for changes in anxiety using the Hamilton Anxiety Rating Scale HAM-A and the Clinical Global Impression Scale-Severity CGI-S at Week 6. Safety and tolerability will also be evaluated. The total duration includes the screening, treatment, and follow-up periods leading up to the primary completion date in October 2027 and study completion in July 2028.

CONDITIONS

Brief Title

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here